November

2024Forupdatedinformation,pleasevisit

BIOTECHNOLOGYExecutive

Summary23Advantage

India5Market

Overview7RecentTrendsand

Strategies11Growth

Drivers18Opportunities22KeyIndustry

Contacts28Appendix31Tableof

ContentsExecutive

summary4.LEADINGDESTINATIONFORCLINICAL

TRIALSTheNewDrugsandClinicalTrialsRules,2019weredevelopedtocreateastreamlinedlegalframeworkforthebiopharmaceuticalmarkettoreducecosts,approvaltimelinesandcutbureaucraticredtape.InOctober2021,drugfirmAstraZenecalaunchedaclinicaldataandinsightsdivisioninBengaluru,India,fordata-relatedmanagementofitsclinical

trials.InNovember2021,US-basedAkstonBiosciencesannouncedthatitwillstartclinicaltrialsofitssecond-generationCovid-19vaccine‘AKS-452’inIndia

soon.Indiais

among

the

top

12biotechnologydestinationsintheworldandthethird-largestinthe

Asia-Pacificregion.Thecountryholds3-5%oftheglobalbiotechnologyindustrypie.Thecountryisalsotheworld’sthird-largestproducerofrecombinantHepatitisBvaccineandsecond-largestproducerofBTcotton.Thecountryisoneoftheworld’sleadingsuppliersofDPT,BCG&measlesvaccines,contributing70%toWHO’s

vaccines.IndiawasoneofthefirstcountriestoestablishaBiotechnology

Department.India’sbio-economyindustryhasgrownfromUS$8billionin2014toUS$100billioninthelast8yearsin2022andreachUS$130billionin2024andUS$300billionby

2030.3.STRONGGROWTHIN

BIOPHARMACEUTICALSIntheIndianbio-economymarket,bio-pharmaceuticalsandmedicaldevicesindustryarethetwolargestsegments,accountingforfornearly79%ofthetotalcontribution.TheIndianbiotechnologyindustrygrowthisdrivenbyvaccinesandrecombinanttherapeutics.By2025,thevaccinationmarketinIndiaisprojectedtobeworthRs.252billion(US$3.04

billion).InJanuary2022,BIRACmadeamajorcontributiontodevelopingtheworld'sfirstIntranasalvaccineforCovidthroughBharatBiotechInternationalLimited(BBIL).InDecember2022,theworld'sfirstCOVID-19intranasalvaccine,iNCOVACCwaslaunched

which

has

been

developed

by

Bharat

Biotech.2.STRONGSTART-UP

ECOSYSTEMIndiahasastrongstart-upecosystem,originatingfromgradualimprovementsintheeaseofdoingbusiness,proof-of-conceptfundsforstart-ups,andfavourablegovernment

policies.ThebiotechnologyindustryinIndiacomprisesUS$130billionin2024and75bio-incubatorsacross21states/UTs

supportingstart-ups,which

are1800+incubates,6,500plus

biotechestimatedtoreach10,000by

2025.1.GLOBAL

POSITION020313234Notes:BTCotton:Geneticallymodifiedpestresistantplantcotton,DPT:diphtheria,pertussis,tetanus,BCG:Bacille

Calmette-GuerinSource:GlobalBio-India2019,BiotechnologyIndustryResearchAssistanceCouncil,FDI

IndiaKeyStatistics:Departmentof

BiotechnologySource:Departmentof

BiotechnologyProjectsSanctionedas

ofOctober

20241,916InternationalCollaborativeProjectsasofOctober

20243ResearchPersonnelas

ofOctober

202448,502Ongoing

Projectsas

ofOctober

20241,547PatentsFiledasof

July20241,171ScientistsSupportedas

ofJuly

202422,128Publicationsas

ofJuly

202422,708TechnologyGeneratedas

ofOctober

20241,0424Advantage

India5Advantage

IndiaADVANTAGEINDIA1432Withatotalpopulationof1.4billion,47%beingundertheageof25,Indiahasalargepoolofyoungandskilled

workforce.Indiahasalargereservoirofscientifichumanresourcesincludingscientistsandengineers.Biotechnologyhasemergedasatrendingcareeroptionamongtheyouth.AccordingtoasurveyofClass12thstudentsinDelhi,Biotechnologywasrankedasthepreferredstreamat

No.4/5.1.Skilledhuman

capitalPatientpoolexpectedtoincreaseover20%inthenext10years,mainlyduetoriseinpopulation.Newdiseases&lifestylechangestoboostdemandfordrugsand

devices.4.Epidemiological

factors9DBT-supportedbiotechparksand60BIRAC-supported

bio-incubators.Singh inaugurates

thefirst

International BiotechDr. JitendraNortheast'sConclave.InFebruary2023,SerumInstituteofIndiaannouncescentreofexcellenceinHyderabadtotacklefuturepandemics.InJuly2023,15companiessignMoUsworthRs.2,000crore(US$239.99million),inaday,forinvestmentsinbiotech

sector.2.Infrastructure

facilitiesSource:DepartmentofBiotechnology,FDIIndiaNationalBiopharmaMissionissupporting101projectsincludingmorethan150organizationsand30MSMEs.Ithasincreasedemploymentopportunitiesandengaged1,065manpowerincluding304scientists/

researchers.While74%ispermittedunderautomaticrouteforbrownfieldprojects,100%undergovernmentrouteispermittedforbrownfield

investments.DPIIT’slaunchedttupSEEDfundschemeisinspiredbyBIRAC’sBIGschemeandguidedbyBIRAC’sMIIcell

interface.TheCabinethasendorsedtheconsolidationoftwoDepartmentofBiotechnology

schemes

into'BiotechnologyResearchInnovationandEntrepreneurshipDevelopment(Bio-RIDE)'withanewBiomanufacturingandBiofoundrycomponent.Theallocatedbudgetfor'Bio-RIDE'isRs.9,197crore(US$1.1billion)for2021-22to2025-26underthe15thfinance

commission.3.Policy

support6Market

Overview7Biotechnology

marketUnionMinisterDr.JitendraSinghstatedthatthenextIndustrialrevolutionwouldbedrivenbytheBioeconomyduringtheCurtainRaiserceremonyofthe'4theditionofGlobalBioIndia2024’

.ThebiotechnologysectorinIndiaiswitnessingastronggrowthtrajectoryandhasprovedtobehighly

inventive.Thebiotechnologysector,mainlyduetoitsmultidisciplinaryapproach,holdsthepotentialtoprovideanarrayofsolutionsforchallengesinvarioussectorssuchashealth,agriculture,environment,energy,andindustrial

processes.Indiaisamongthetop12biotechnologydestinationsintheworldandthethird-largestintheAsia-Pacificregion.TheIndianbiotechindustryholdsabout3%oftheglobalmarket

share.ThegrowthoftheIndianbiotechnologysectorisdrivenbyincreasingdemandbothdomesticallyandinternationally.InitiativeslikeAatmanirbharBharatandMakeInIndiaarekeyfactorscontributingtotheriseindomestic

demand.Indiaexportsvaccinestomorethan150countriesandisaprimedestinationforcontractmanufacturingandclinical

trials.India’sbio-economyindustryhasgrownfromUS$10billionin2015toUS$130billionin

2024.TheIndianbiotechnologyindustryislikelytoreachUS$150billionby2025andhasthepotentialtoreachUS$270-300billionbytheyear

2030.By2025,thecontributionoftheIndianbiotechnologyindustryintheglobalbiotechnologymarketisexpectedtoincreaseto

~19%.Indiahas665FDA-approvedplantsoutsideoftheUS,whichisthehighestintheworld.Indiaalsohasa44%shareoftheglobalabbreviatednewdrugapplications(ANDA)and>1400manufacturingplantswhichcomplywithWHO

requirements.Notes:FDA:FoodandDrug

AdministrationSource:DPT-BIRAC,AssociationofBiotechnologyLedEnterprises

(ABLE)445163300050300250200150 130100350FY17FY18FY19FY24FY30EIndianbiotechnologyindustryvaluation(US$

billion)CAGR

15.8%Indianbioeconomyataglance

(2023)US$12

billionIndia’sBiotechIndustry

Revenue1

millionIndia’s

BiotechWorkforce6,000+Biotech

Companiesin

India15,500+Biotech

GraduatesEvery

Year8Indianbiotechnologysectorisdividedintofive

segmentsBiopharmaBiosimilarsVaccinesInsulinRegenerative

medicinesMedical

devicesBio-ServicesContract

manufacturingClinical

researchBio-AgriHybrid

seedsBio-fertilisersBio-pesticidesBioindustrialBiofuelsIndustrial

enzymesBio-polymersBio-ITBio-infomaticsBig

dataPrecision

medicineSource:AssociationofBiotechnologyLedEnterprises

(ABLE)Biotechnology910BioconIndianpharmaceuticalcompanybasedinBangalorethatmanufacturesgenericactive

pharmaceuticalingredients.SerumInstitute

ofIndiaManufacturerofimmuno-biologicals,whichincludeDiphtheria,Tetanus,Pertussis,Hib,BCG,

r-HepatitisB,Measles,MumpsandRubella

vaccines.Panacea

BiotecLimitedInnovation-drivenbiotechnologycompany,undertakingresearchanddevelopment,manufacturing,sales,distributionandmarketingofpharmaceuticals,vaccinesand

biosimilars.DrReddy’sLaboratory

LimitedIntegratedpharmaceuticalcompany,providingaffordableandinnovative

medicines.WockhardtGlobalpharmaceuticalandbiotechnologyorganisation,manufacturingpharmaceuticals,biopharmaceuticalformulationsandactivepharmaceutical

ingredients.JubilantLife

SciencesCoIntegratedglobalpharmaceuticalandlifesciencescompany,engagedinpharmaceuticals,lifescienceingredients,drugdiscoverysolutionsandIndia-brandedpharmaceuticals.AstraZenecaPharmaIndia

Ltd.IndianbiopharmaceuticalcompanybasedinBengaluruthatmanufacturescardiovascular,renalandmetabolicdiseases,oncology,andrespiratory

medicines.BharatSerums

andVaccines

LtdIndianpharmaceuticalcompanybasedinMumbaithatmanufacturesplasmaderivatives,monoclonals,fertilityhormones,antitoxins,antifungals,anaesthetics,cardiovasculardrugsanddiagnostic

products.IndianImmunologicals

LtdIndianbiopharmaceuticalcompanybasedinHyderabadthatmanufacturesanimalandhumanvaccineincludingrabies,HepatitisB,DiptheriaandInfluenza

vaccines.Bharat

BiotechIndianbiotechnologycompanybasedinHyderabadthatengagesindrugdiscovery,drugdevelopmentaswellasmanufacturesvaccines,bio-therapeutics,pharmaceuticalsandhealthcare

products.Note:News

ArticlesKey

players本報(bào)告來(lái)源于三個(gè)皮匠報(bào)告站（）,由用戶Id:879887下載,文檔Id:619128,下載日期:2025-03-26RecentTrendsand

Strategies11Nationalandinternational

partnershipsNotes:BIRAC:BiotechnologyIndustryResearchAssistance

CouncilSource:CompanyWebsite,News

ArticlesInJune2022,SerumInstituteofIndiapartneredwithUScompanyNovavax

tomanufacturetheirCovidvaccine(NVX-CoV2373)fortheUSmarket.SerumInstituteofIndiatomanufactureNovavax'sCovidvaccineforthe

USmarketOneHealthConsortiumInOctober2021,

theDepartmentofBiotechnologylauncheda‘OneHealth’consortiumthatwillsurveyimportantbacterial,viralandparasiticinfectionsofzoonoticaswellastransboundarypathogensinthecountry.Theconsortiumconsistsof27organisations,andisledbytheDBT-NationalInstituteofAnimalBiotechnology,Hyderabad.Partnershipbetween

MylabSolutions&ShilpaBiologicalsInFebruary2022,Pune-basedMylabDiscovery

SolutionsenteredintoastrategicpartnershipwithShilpaBiologicals,asubsidiaryofShilpaMedicare,tomanufacturevaccinesandtherapeutics,startingwiththeCovid-19

vaccine.InFebruary2022,DBTinkedafive-yearMoUwiththeIndianCouncilofMedicalResearch(ICMR)and

IAVI.INOVIO’sINNOVATEPhase

3Trialfor

Covid-19DNAVaccineinIndiaInNovember2021,INOVIOannouncedthatithasreceivedauthorisationfromIndia'sCentral

DrugsStandardControlOrganization’s(CDSCO)

DrugControllerGeneral

ofIndia(DCGI)toproceedwiththePhase3segmentofINNOVATE

(INOVIOINO-4800VaccineTrialforEfficacy)

inIndia.INOVIO

ispartneringwithAdvaccineBiopharmaceuticalsSuzhouCo.,Ltd.(Advaccine)toconductthe

trials.WHOissued

EULfor

COVAXINInNovember2021,theWorldHealthOrganization(WHO)issuedanemergencyuselisting(EUL)forBharatBiotech’sCovid-19vaccineCOVAXIN.Itwasfoundtohave78%efficacyagainst

Covid-19virusofanyseverity.TwoPSUsinkpactwithCovaxin

makerBharatBiotechtomanufacture

COVIDvaccinesInMay2021,IndianImmunologicalsLimited(IIL)andBharatImmunologicalsandBiologicalsCorporation(BIBCOL)signedtechnologytransferpactswithBharatBiotechtodevelopthevaccinelocallytoboostIndia'svaccination

drive.IILstartedsupplying

thevaccinestoBharatBiotechinAugust

2021,whileBIBCOLplanstofinishproductionofthetrialbatchofCovaxininFebruary

2022.12Recent

DevelopmentsIndia

allows

100%

FDI

under

the

automatic

route

(a

non-resident

or

Indian

company

will

not

require

any

approval

from

the

government)

for

greenfieldpharmaceuticalsandmanufacturingmedical

devices.2023-24IntheFY24,India'spharmaceuticalexportsincreasedby9.67%toreachUS$27.9billion.TheUnitedStatescontinuestobethelargestmarket,accounting

for

more

than

31%

of

the

exports,

with

the

UK

and

the

Netherlands

following.In

March

2024,Union

Minister

of

Science

&

Technology,

Dr.

Jitendra

Singh,

inaugurated

the

pioneering

"National

Speed

Breeding

Crop

Facility"

at

theNationalAgri-FoodBiotechnologyInstitute

(NABI)inMohali.InJanuary2024,UnionMinisterofState(IndependentCharge)Science&Technology,DrJitendraSinghinaugurationofBiotechStartupsExpoon“Emerging

Startup

Trends

in

North

India

at

Biotech

Park,

Kathua.InDecember2023,theGujaratChiefMinisteralsoinauguratedthe‘Start-UpProductLaunch’whichincludedinnovativeproductsdevelopedbystartupssuchasBioscan,SynerSense,Iota,andSTRUmedSolutionsduringthe10thVibrantGujaratGlobalSummit.ThePre-Summitalsowitnessedthesigning

of

a

Memorandum

of

Understanding

(MoU)between

Indus

Setu

Global

Foundation

and

Gujarat

State

Biotechnology

Mission.InNovember2023,BharatBiotechsignsMoUwithUniversityofSydneyInfectiousDiseasesInstitute(SydneyID)tocollaborateonvaccineresearchinitiativesandstrengthenacademic-industry

partnerships.In

October

2023,

the

Uttarakhand

government

signed

several

MoUs

worth

Rs.

5,450

crore

(US$

653.97

million)

with

industrial

bodies

in

Dubai.InAugust2023,CSIR-NationalInstituteofScienceCommunicationandPolicyResearch(NIScPR)publishedaspecialissueoftheIndianJournalofBiochemistry

and

Biophysics

(IJBB)

on

Biological

Electron

Microscopy

and

Nanobiotechnology.InAugust2023,theDepartmentofBiotechnology(DBT)andtheUnitedStates-NationalScienceFoundation(US-NSF)announcedtobuildbilateralcollaborations

between

India

and

the

USA

through

this

Implementation

Arrangement.InAugust2023,theTechnologyDevelopmentBoard(TDB)andtheDepartmentofScience&Technology(DST)partneredwithChemlifeInnovationsfortheInnovativeBio-TraceMineralsProjecttoenhancelivestockproductivity,optimizefeedandfodderresourcesandinfusetechnologyintolivestockmanagement.InJuly2023,NationalBiopharmaMissionissupporting101projectsincludingmorethan150organizationsand30MSMEs.Ithasincreasedemployment

opportunities

and

engaged

1,065

manpower

including

304

scientists/

researchers.In

July

2023,

Aurigene

Pharmaceutical

Services

to

set

up

US$

40

million

facility

in

Hyderabad.In

April

2023,

under

the

Biotech-KISAN

scheme,

160,000

farmers

received

benefits

during

the

last

one-year(January-December

2022).Note:CSIR-CMERI-CouncilofScientific&IndustrialResearch-CentralMechanicalEngineeringResearch

InstituteSource:NewsArticles,ABLE

India13Recent

Developments2022-23InDecember2022,UnionHealthMinisterDr.MansukhMandaviyaandtheMinisterofState,MinistryofScienceandTechnology,EarthScience,Personnel,PublicGrievances,Pensions,SpaceandAtomicEnergyMinister,Dr.JitendraSinghlaunchedtheworld'sfirstCOVID-19intranasalvaccine,

iNCOVACC,

which

has

been

developed

by

Bharat

Biotech.InDecember2022,Bengaluru-headquarteredCentreforCellularandMolecularPlatforms(C-CAMP),aninitiativesupportedbytheDepartmentofBiotechnology,

announced

a

next-generation

Indo-Dutch

bilateral

collaboration

to

address

challenges

posed

by

Antimicrobial

Resistance

(AMR).InDecember2022,theDepartmentofBiotechnologyhasfinanced51Biotech-Kisancentres,ofwhich44areoperational.Thesecentresarespreadacross15agro-climaticregionsofthenationandoperatein169

districts.InNovember2022,YaraIndia,whichispartoftheOslo-based,NorwegianmultinationalYaraInternational,hastiedupwithaBengaluru-basedstart-up

and

ABLE

Member

Sea6

Energy,

to

market

and

distribute

its

bio-stimulant

AG

Boost

in

India.OnNovember14th,2022,IndiaandFinlandagreedtoadvancebilateralcollaborationandexpandcooperationinsectorslikedigitaleducation,futuremobile

technologies,

biotechnology,

and

the

digital

partnership

in

ICT.InFY22,India’spharmaceuticalexportstouchedRs.1.8trillion(US$23.04billion).Formulationsandbiologicalsaccountfor73.31%ofthecountry'stotal

exports,

followed

by

bulk

drugs

and

drug

intermediates.InFebruary2022,GenovaBiopharmaceuticals,whowereconductingphase2and3trialsofIndia’sfirstindigenousmRNAvaccineonhumans,finished

those

trials.

The

data

is

currently

being

reviewed

by

the

Drug

Controller

General

of

India

(DCGI).InFebruary2022,AmericanbiotechcompanyVaxartannouncedplanstostartphaseIIclinicaltrialsofitsoraltablet-basedCovid-19vaccineinIndia

soon.InFebruary2022,Indiaadministeredtheworld’sfirstDNAvaccine–ZYCOV-DinPatna,whichwasdevelopedbyAhmedabad-basedvaccinemanufacturerZydus

Cadila.In

February

2022,

the

MalaysianDrug

Control

Authority

(DCA)approved

Bharat

Biotech’s

Covaxin

to

be

used

in

Malaysia.InFebruary2022,DCGAofIndiagrantedrestrictedemergencyuseauthorisationtoBiologicalE'sCovid-19vaccineCorbevaxforkidsinthe12-18yearsage

bracket.InFebruary2022,UnionMinisterDr.JitendraSinghinauguratestheNortheast'sfirstInternationalBiotech

Conclave.InFebruary2022,theIndiangovernmenthasacceptedtoannounceanewinitiativetoencouragepharmaceuticalresearchanddevelopment(R&D)intheUnionBudgetfor

2023-24.Note:CSIR-CMERI-CouncilofScientific&IndustrialResearch-CentralMechanicalEngineeringResearch

InstituteSource:NewsArticles,ABLE

India14NationalBiopharma

MissionNotes:GCLP:Goodclinicallaboratorypractice,GLP:Goodlaboratorypractice,EMI:Electromagneticinterference,EMC:electromagneticcompatibility,PDL:preferreddruglist,GMP:Goodmanufacturing

practicesSource:Departmentof

BiotechnologyStrengthening

EcosystemFacilitiesGCLPlabforclinicalimmunogenicity,cell

linerepository,

PDL+GMPGLPlabforbiologics,celllinerepository,

PDL+GMPEMI/EMCtestingfacility,largeanimaltestingfacility,prototyping

facilitiesTraditionalresearch

consortiaViral

repositoriesHighthroughput

assaysAnimal

modelsRawmaterialsNovel

biologicsTechnologyplatformsAnimal

modelsNovel

assaysNovelcelllines

developmentIndigenousmanufacturingtechniquesCore

technologydevelopmentEnhancing

clinicaltrial

capacityFieldsitecapacities

forclinical

trialsHospitalbasedclinical

trialnetworksHospitalbasedclinical

trialnetworksSkill

developmentThemissionengagedBiotechConsortiumIndiaLimited(BCIL)toorganiseaseriesof

lecture-basedworkshopstofacilitateskilldevelopmenttobuildnext-generationinterdisciplinaryskillsforproductinnovationsacrossthe

countryTechnologytransfer

officesEstablished‘TechnologyTransferOffices’tosupporttechnologytransferand

entrepreneurshipAffordable

Products15Vaccines Biosimilars Medical

devicesDevelopingSpecificProductsAtalJaiAnusandhanBiotech

MissionAtalJai

Anusandhan

Biotech

Mission

is

implemented

by

Department

ofBiotechnology

(DBT),

Ministry

of

Science

andTechnology.The

purpose

of

this

mission

is

to

address

the

challenges

of

maternal

and

child

health,

antimicrobial

resistance,

vaccines

forinfectious

disease,

food

and

nutrition,

and

clean

technologies.Ind-CEPI–vacciniesforendemicpreparedessUNATIMissionCleanTechnologiesforSwachh

BharatGARBH-IniformentalandchildhealtBifortifiedandproteinrichwheatforPoshanAbhiyanGlobalAntimicrobialResistanceResearchandDevelopmentHubforaffordable

healthSource:Departmentof

Biotechnology16AtalJaiAnusandhanBiotech

MissionState-specific

policies17Source:StateGovernment

WebsiteSouthAndhra

PradeshBiotechnologyPolicy

2015-2020Enhance

Andhra

Pradesh's

competitiveness

as

a

top

biotech

investment

destination,

creating

5,000

skilled

jobs

by2020and10,000by

2025.KarnatakaBiotechnologyPolicy

2023-2028Buildingonastrongfoundation,thispolicyaimstotransformKarnatakabiotechsectorthroughimpactfulimplementation,synergizingwithexistingstatepoliciesforexponential

growth.TelanganaLifeSciencesPolicy

2015-2020Developmentofsuitableinfrastructuretoattractlifesciencecompaniesandbecomealeading

investmentdestinationinthe

sector.NorthUttarakhandBiotechnologyPolicy

2018-2023AimstoattractnewinvestmentsworthUS$709millioninthesector;generateemploymentopportunitiesfor5000peopleby

2023.Himachal

PradeshBiotechnologyPolicy

2014AimstomakeHimachalagloballycompetitivedestinationfordevelopmentofbiotechnologyproducts,processesand

services.WestRajasthanBiotechnologyPolicy

2015Aims

to

establish

world-class

research

institutes

and

biomanufacturing

infrastructure.GujaratBiotechnologyPolicy

2022-27TomakeGujaratapreferredandgloballycompetitivedestinationfordevelopmentofbiotechnologyproductsandservices.EastAssamBiotechnologyPolicy

2018-2022DevelopmentofthebiotechnologyindustryinAssam,followingthegrowthofbio-agrisegmentinthe

state.OdishaBiotechnologyPolicy

2024TotransformOdishaintoagloballyrecognizedbiotechnologyhubandprogressivebio-economybyleveraging

itsnaturalbioresources,humanresources,andknowledge

capital.CentralMadhyaPradeshBiotechnologyPolicy

2003Conservationandsustainableutilisationofbio-resourcestopromotesocioeconomicgrowthinthe

state.Growth

Drivers18Strongdemandandpolicysupportdriving

investmentsInvitingResulting

inGrowing

demandPolicy

supportIncreasing

investmentRisingdemand

foragriculture-basedproductsGrowingincidenceofchronic

ailmentsDemandforpersonalisedmedicinesandbiosimilars100%FDIunderautomaticroute

forgreenfield

projects100%FDI

undergovernmentroute

forbrownfieldinvestments74%FDIunderautomaticroute

forbrownfieldinvestmentsExpandingproductionanddistribution

facilitiesin

IndiaIncreasingR&D

activitiesProvidingsupport

toglobal

projectsEstablishingLSSSDCunderNSDCto

promoteskilldevelopmentinthelifesciences

sectorNotes:LSSSDC:LifeSciencesSectorSkillDevelopmentCouncil,NSDC:NationalSkillDevelopmentCorporation,R&D-Researchand

DevelopmentSource:DepartmentofBiotechnology,AssociationofBiotechnologyLedEnterprises

(ABLE)19Ecosystemfor

start-upsThestart-upecosysteminIndiaisstronglysupportedonthebackofgradualimprovementsintheeaseofdoingbusiness,proof-of-conceptfundsforstart-upsandfavorablegovernment

policies.ThebiotechnologysectorhaswitnessedasignificantriseinnewstartupregistrationsacroVsissathkehanpaatiotnnaimnp20o2r1t,trwaiftfhica(pmpriollxioimnattoenlyn1e,s1)28freshstartupsenteringthemarket.Thissurgehascontributedtotheoverallcountofbiotechnologystartupsreachingaround6,000bytheyear

2023.BIRAC,apublicsectorundertakingofDBT,partneredwithinnovativefoundationsanduniversitiestofocuson‘MakeinIndia’and‘Start-upIndia’

programmes.BIRACestablishedseveralindustry-focussedschemessuchasSBIRI,BIPPBiotechnologyIgnitionGrant,BioNEST,SITARE,PACE,SIIP,SEED,LEAPandFundofFunds-AcE.BIRAChassupported60bio-incubatorsforpotential

entrepreneurs.In

July

2023,

India

and

Argentina

agreed

to

a

bilateral

exchange

of

youngresearchers

and

Startups,

particularly

in

the

field

of

Biotechnology

and

Agriculture.InMay2023,IndiaandIsraelwillstrengthentheirconnectioninareassuchasinnovationandstart-ups,usheringinanewperiodofdeeperbilateralcooperation.TheDepartmentofBiotechnology(DBT)oftheMinistryofScienceandTechnologyinIndia,andUNESCO-TWASestablishedafellowshipprogrammeforforeignscholarsfromdevelopingcountri